Sarepta reports second patient death after treatment with Duchenne gene therapy

Taking stock of the drug industry, from the lab to the medicine chest

June 16, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe STAT+ | After second Sarepta death, Duchenne muscular dystrophy community is racked by recrimination and worry Second death linked to Sarepta Therapeutics treatment leaves Duchenne muscular dystrophy community reeling, Elevidys use halted in non-ambulatory patients. By Adam Feuerstein and Jason Mast STAT+ | Lilly's amylin candidate shows early promise  Today's biotech news covers the second death tied to Sarepta's Duchenne treatment, Wojcicki's nonprofit winning the 23andMe bidding war, etc. By Meghana Keshavan STAT+ | Hospitals would be hit hardest by Medicaid cuts in GOP tax bill, report finds To finance tax cuts, the bill would reduce Medicaid payments to hospitals by $321 billion, hitting both blue and red states, a report finds. By John Wilkerson Kent Dayton/Harvard T.H. Chan School of Public Health STAT+ | Private equity firm will finance Harvard research lab, in possible template for future Turkish private equity firm commits $39 million to support research by Gökhan Hotamışlıgil, with option to invest in future drug candidates from his lab. By Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser